Drug Profile
Research programme: next generation neoantigen-based cancer immunotherapeutics - Immune Design
Alternative Names: LA 51; Zvex IL12; ZVex-IL12; ZVex/IL-12Latest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator Immune Design
- Class Antineoplastics; Cancer vaccines; Immunotherapies
- Mechanism of Action Cytotoxic T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for preclinical development in Cancer in USA (Intratumoural)
- 24 Jul 2017 Preclinical trials in Cancer in USA (Intratumoural) before July 2017 (Immune Design pipeline, July 2017)